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BACKGROUND: As part of the Magnetic Resonance Imaging for Breast Screening (MARIBS), Study women with a family history of
breast cancer were assessed psychologically to determine the relative psychological impact and acceptability of annual screening using
magnetic resonance imaging (MRI) and conventional X-ray mammography (XRM).
METHODS: Women were assessed psychologically at baseline (4 weeks before MRI and XRM), immediately before, and immediately
after, both MRI and XRM, and at follow-up (6 weeks after the scans).
RESULTS: Overall, both procedures were found to be acceptable with high levels of satisfaction (MRI, 96.3% and XRM, 97.7%; NS) and
low levels of psychological morbidity throughout, particularly at 6-week follow-up. Low levels of self-reported distress were reported
for both procedures (MRI, 13.5% and XRM, 7.8%), although MRI was more distressing (P¼ 0.005). Similarly, higher anticipatory
anxiety was reported before MRI than before XRM (P¼ 0.003). Relative to XRM, MRI-related distress was more likely to persist at
6 weeks after the scans in the form of intrusive MRI-related thoughts (P¼ 0.006) and total MRI-related distress (P¼ 0.014). More
women stated that they intended to return for XRM (96.3%) than for MRI (88%; Po0.0005). These effects were most marked for
the first year of screening, although they were also statistically significant in subsequent years.
CONCLUSION: Given the proven benefits of MRI in screening for breast cancer in this population, these data point to the urgent need
to provide timely information and support to women undergoing MRI.
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Women with a known family history of breast cancer, or of a
predisposing gene mutation such as BRCA1 or BRCA2, have a
cumulative lifetime risk of 45–65% (Antoniou et al, 2003), and a
significant number of these cancers are diagnosed before the age of
50 years. A number of prevention strategies have been identified
for these women, including bilateral prophylactic mastectomy,
chemoprevention, and screening with annual X-ray mammo-
graphy (XRM). Prophylactic mastectomy remains unacceptable to
the majority of mutation carriers for a variety of reasons, including
the prospect of mutilating surgery, loss of sensation, and breast
cancer not being totally preventable (Warner, 2004). There is also
some concern about the poor sensitivity of XRM because of the
difficulties in evaluating X-ray mammograms from dense tissue in
younger, premenopausal women and the concern that the tumours
resulting from gene mutations may be particularly aggressive
(Liberman, 2004).
There has been a growing interest in the use of breast magnetic
resonance imaging (MRI), and a number of studies have been
undertaken to assess the benefits of adding MRI to XRM in
screening young women at high risk of breast cancer. A recent
systematic review of these studies (Lord et al, 2007) found
consistent evidence that adding MRI to XRM provides a highly
sensitive screening strategy (sensitivity range: 93–100%) com-
pared with XRM alone (25–59%) or with XRM plus ultrasound
with or without clinical breast examination (25–59%). A cost-
effectiveness analysis of the UK Magnetic Resonance Imaging
for Breast Screening (MARIBS) study evaluated the incremental
cost per cancer detected by XRM and XRM plus MRI, and
concluded that adding MRI to XRM is potentially cost-effective for
women at high familial risk of breast cancer, particularly for
BRCA1 and BRCA2 mutation carriers (Griebsch et al, 2006). The
compelling evidence for the benefits of MRI has translated into UK
National Institute for Clinical Excellence (NICE) guidelines, which
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now recommend that women who are known mutation carriers, or
who are at substantially increased familial risk, should be offered
annual MRI surveillance (McIntosh et al, 2006).
A systematic review of the psychological impact of XRM for
screening women with a family history of breast cancer concluded
that women do not seem to experience high levels of anxiety
associated with XRM, but may experience slight increases in the
short term. Interpretation of studies evaluating the psycho-
logical impact of XRM, however, is hampered by the heterogeneity
of the measures used, the use of non-validated measures, small
sample sizes, and the lack of a baseline measure of anxiety
uncontaminated by the knowledge of an impending screening
appointment (Watson et al, 2005).
Two studies have compared the psychological effects of MRI
plus XRM with XRM alone for screening women at high risk of
breast cancer. In the Dutch study (Van Dooren et al, 2005),
psychological distress remained within normal limits throughout
screening for the group as a whole (n¼ 357). However, elevated
breast cancer-specific distress related to screening was found in
women who did ‘excessive’ breast self-examination (defined as at
least once per week), risk over-estimators, and women closely
involved in the breast cancer care of a sister. In a sample of women
from the Toronto study followed up over the course of 2 years,
there was no evidence of any effect on global anxiety, depression,
or breast cancer-related anxiety. However, only 57 women were
recruited and, of those, 28 completed at least one assessment and
25 completed at least three (Warner, 2004).
Potentially, annual breast MRI could be extremely distressing.
The procedure can take upwards of 50min; the MRI scanner can
be claustrophobic and noisy, and the positioning of the participant
at an angle, higher in the bore, where the bore is narrower may
make the procedure more claustrophobic (Anderson and Walker,
2002). Psychological reactions to MRI vary considerably and it has
been reported that 25–37% of MRI participants experience
moderate to severe claustrophobia (Katz et al, 1994; McIsaac
et al, 1998).
The present study represents the largest and most comprehen-
sive study to date of the psychological impact and acceptability of
annual MRI plus XRM, compared with XRM alone, in women with
a family history of breast cancer.
MATERIALS AND METHODS
The MARIBS study, funded by the United Kingdom Medical
Research Council, was a multicentre study to compare the
sensitivity, specificity, cost-effectiveness, and psychosocial impact
of annual XRM with XRM plus MRI in young women with a family
history of breast cancer. The rationale, protocol, and outcome for
the overall study have been reported, and the radiological and
economic aspects have been detailed elsewhere (Brown et al,
2000a, b; Leach et al, 2005; Warren et al, 2005, 2006a, b; Griebsch
et al, 2006; Gilbert et al, 2009)
Women between the age of 35 and 50 years were recruited
between 1997 and 2004, from 22 Genetics Departments across
the United Kingdom. To be eligible, women had to meet at
least one of the following criteria: they had to be tested carriers
of a deleterious BRCA1, BRCA2, or TP53 mutation; be first-degree
relative of someone with a BRCA1, BRCA2, or TP53 mutation,
or a strong family history of breast and/or ovarian cancer.
All participants were offered annual screening with both contrast-
enhanced MRI and XRM. X-ray mammography was performed
according to the standards of the National Health Service
Breast Screening Programme. Magnetic resonance imaging
was undertaken using a specified protocol (Warren et al,
2005) and gadopentetate dimeglumine (Magnevist, Schering
Healthcare, Burgess Hill, West Sussex, UK). Both XRM and MRI
were independently double reported.
To determine the relative psychological impact and acceptability
of MRI and XRM, women were assessed at baseline (by 4 weeks
before MRI and XRM), immediately before both MRI and
XRM, immediately after both MRI and XRM, and at follow-up
(6 weeks after the scans). Booklets for each time point were
professionally printed and contained standardised question-
naires to evaluate various psychosocial outcomes and ad hoc
questions to document sociodemographic characteristics, previous
experiences of mammography, intention to return for further
screening, and patient satisfaction. (Copies of the booklets are
available on application to the first author.) The booklets were
printed in a format that permitted optical character recognition
and automatic scoring. (The booklets were printed and scored
by KendataPrint Services, Nutsay Lane, Totton, Southampton
SO40 3NB, UK.)
The standardised questionnaires were as follows:
The Hospital Anxiety and Depression Scale (HADS) (Zigmond and
Snaith, 1983): The HADS is a widely used, 14-item, self-report,
screening tool for anxiety and depression. It is easy to administer
and is well accepted, and has been designed to be especially rele-
vant for the somatic medicine setting rather than mental health
(Hermann, 1997). Its performance and psychometric properties have
been established as a screening tool in a cancer setting
(Walker et al, 2007), and it has been used previously to evaluate
the psychosocial effects of breast screening in women with a family
history of breast cancer within the context of the UK Breast
Screening Programme (Gilbert et al, 1998). It is customary to analyse
HADS data in two ways: mean scores (for the anxiety and depression
scales) and total scores, and proportions of patients scoring in the
‘normal’ (0–7), ‘borderline’ (8–10), and ‘clinically significant’
(411) ranges. Scores on each scale can range from 0 to 14.
The Health Questionnaire (HQ) (Walker et al, 1994): This is a seven-
item, self-report scale of self-perceived stress-related behaviour
change. Respondents indicate for each stress-sensitive behaviour
whether, in the last week, it has been ‘better than normal’ (score 0),
‘normal’ (score 1), or ‘worse than normal’ (score 2). The scale has
been validated with the HADS and used to evaluate the immediate
emotional and behavioural effects of attending XRM within the UK
National Breast Screening Programme. In this context, it was shown
to be sensitive to the effects of attending screening (Walker et al,
1994) and also having a false-positive recall (Gilbert et al, 1998).
The Spielberger State Anxiety Inventory (SSAI-B, brief form)
(Marteau and Bekker, 1992): The SSAI-B is a shortened version
(6-item) of the 20-item original scale, which asks how a person
feels now and reflects situational factors that may influence anxiety
levels (Spielberger et al, 1983). The brief form has been validated
against the full form and has been shown to have acceptable
reliability and validity (Marteau and Bekker, 1992). As in the
original scale, each item is scored on a 1–4 scale. If desired, scores
on the brief scale can be pro-rated (multiply by 3.333) to render
them comparable with scores obtained using the full scale. Norms
for the full scale for various populations have been published
(Spielberger et al, 1983).
Impact of Events (IoE) scale (Horowitz et al, 1979): This is a
15-item scale, whereby respondents rate the frequency with which
they have experienced intrusive images and avoidance behaviour
related to a specific life event in the last 7 days. In addition to
measuring intrusion and avoidance, total scores can be used to
assess total subjective distress. Each item is scored according to the
frequency with which the respondent has had the experience
described in the previous 7 days (‘not at all’ scores 0, ‘rarely’
scores 1, ‘sometimes’ scores 3, and ‘often’ scores 5). Thus, the total
score can range from 0 to 75.
The IoE was administered twice at follow-up, once anchored to
XRM, and once anchored to MRI.
Assessments were carried out at the following time points:
Baseline (4 weeks before the scans): Information was collected
for sociodemographic characteristics and previous screening
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experiences, and the HADS and HQ were administered. Women
were sent the baseline booklet by post and were asked to return it
in advance of screening in the enclosed stamped envelope
addressed to the Research Assistant at the Institute of Rehabilita-
tion, University of Hull, UK.
Immediately before MRI and immediately before XRM: The HADS,
HQ, and SSAI-B were administered. Women were given the pre-
and post-scan booklets by radiographers according to a standar-
dised protocol.
Immediately after MRI and immediately after XRM: Information
was collected regarding acceptability, distress caused by proce-
dure, and satisfaction with procedure, and the SSAI-B was
administered. Women were given the pre- and post-scan booklets
by radiographers according to a standardised protocol.
Follow-up: The HADS, HQ, and IoE were administered and
intention to return for screening was assessed. Women were sent
the follow-up booklet by post, and they were asked to return it in
an enclosed stamped envelope addressed to the Research Assistant
at the Institute of Rehabilitation, University of Hull, UK. Women
who had not responded within a week were sent reminders and
given a further week to respond. Questionnaires received after this
time were excluded from the analyses.
Analysis plan
There were two primary end points, both in year 1: immediate
effects of MRI and XRM (as soon as the procedure had been
completed), and the delayed effects of MRI and XRM (at 6-week
follow-up).
The primary immediate outcome measure was scores on the
SSAI-B, and the primary follow-up outcome measurement was
total scores on the IoE scale.
Secondary immediate outcome measures of the two procedures
were the HADS, HQ, and ad hoc items relating to acceptability,
distress, and satisfaction. Secondary delayed outcome measures
were the HADS, HQ, and ad hoc items relating to intention to
return.
The MARIBS Study was designed to have adequate power to test
the primary study hypothesis, namely, that MRI can be used with
equal or better sensitivity than XRM, with an acceptable false-
positive rate, rather than to detect differences in psychological
variables (Brown et al, 2000a, b). However, in terms of primary
psychological outcomes, the power to detect a one-point difference
between the two procedures using the SSAI-B was 97%, and the
power to detect a 1.5-point difference using the IoE total score was
also 97%.
Data were analysed using t-tests, Mann–Whitney U-tests, and
w2-test as appropriate. a-Value was set at 0.05 for two-tailed tests.
RESULTS
Recruitment and retention
Over the 5 years of continuing recruitment to the psychology
study, 616 women (97% of all women screened for MARIBS) were
recruited for their first screening round; 411 (84% of all women
screened) returned for year 2 MRI and XRM; 261 (72% of all
women screened) in year 3; 160 (68% of all women screened) in
year 4, and 49 (39% of all women screened) in year 5. Figure 1
shows the number of women recruited to the psychological arm of
the study and the response rates for each of the assessments. It also
shows the number of cancers detected each year.
Of all women invited to take part in the MARIBS 58% accepted
the invitation following genetic counselling. This acceptance rate
has been published previously (Evans et al, 2001).
Table 1 describes the sociodemographic details of the study
participants, their previous screening experiences, and scores on
the psychological measures at baseline (1 month before MRI and
XRM).
Baseline characteristics
Hospital Anxiety and Depression Scale depression scores were
highest at baseline, and significantly higher than immediately before
MRI (t¼ 3.38, P¼ 0.001, CI: 0.28–1.05). This difference in
depression scores accounts for the significantly higher level of total
distress (HADS) at baseline, compared with immediately before
MRI (t¼ 2.60, P¼ 0.009, CI: 0.26–1.87). This difference was not
related to having had a previous MRI scan (t¼0.74, P¼ 0.46,
CI: 0.90 to 0.41) or to having previously found MRI distressing
(t¼ 1.57, P¼ 0.12, CI: 0.36 to 3.11). Hospital Anxiety and
Depression Scale anxiety scores were relatively constant throughout.
In terms of clinically significant categories on the HADS, there
were no significant differences in the proportion of women falling
into the normal, borderline, or clinically significant categories of
anxiety at baseline compared with pre-MRI values (w2¼ 5.27,
P¼ 0.26, CI: 0.26–0.27), or in the numbers of women falling into
the normal, borderline, or clinically significant categories of
Year 1
632 Eligible women
screened for
MARIBS study;
616  (97%) completed
questionnaires
66 Women officially
withdrew from the
MARIBS study;
24 women completed
the study (due to
continuous
recruitment)
Year 2
492 Eligible women
screened for
MARIBS study;
411 (84%) completed
questionnaires
Response rates
B’ground 281 (68%)
Pre MRI 342 (83%)
Pre XRM 296 (72%)
Post MRI 345 (84%)
Post XRM 303 (74%)
Follow-up 287 (70%)
35 Women officially
withdrew from the
MARIBS study;
106 women completed
the study (due to
continuous
recruitment)
Year 3
363 Eligible women
screened for
MARIBS study;
261 (72%) completed
questionnaires
Response rates
B’ground 172 (66%)
Pre MRI 204 (78%)
Pre XRM 179 (69%)
Post MRI 208 (80%)
Post XRM 180 (69%)
Follow-up 169 (65%)
Year 4
235 Eligible women
screened for
MARIBS study;
160 (68%) completed
questionnaires
Response rates
B’ground 103 (64%)
Pre MRI 122 (76%)
Pre XRM 97 (61%)
Post MRI 122 (76%)
Post XRM 110 (69%)
Follow-up 108 (68%)
Year 5
126 Eligible women
screened for
MARIBS study;
49 (39%) completed
questionnaires
Response rates
B’ground 29 (59%)
Pre MRI 38 (78%)
Pre XRM 31 (63%)
Post MRI 36 (73%)
Post XRM 36 (73%)
Follow-up 28 (57%)
19 Women officially
withdrew from the
MARIBS study;
113 women completed
the study (due to
continuous
recruitment)
12 Women officially
withdrew from the
study;
111 women completed
the study (due to
continuous
recruitment)
17 Cancers detected + 1
interval cancer
6 Cancers detected
4 Cancers detected
3 Cancers detected
3 Cancers detected
Response rates
B’ground 527 (86%)
Pre MRI 556 (90%)
Pre XRM 436 (71%)
Post MRI 562 (91%)
Post XRM 441 (72%)
Follow-up 481 (78%)
Figure 1 Trial profile. Numbers of women who were screened each
year for MARIBS, number of participants in the psychology study, the
response rates for each of the assessments (includes the number of women
who withdrew or were withdrawn because of a cancer diagnosis), and the
number of women who completed the study by year (because of
continuous recruitment over the 5-year period).
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depression at baseline compared with pre MRI (w2¼ 1.11, P¼ 0.89,
CI: 0.92–0.93).
Outcomes immediately before and after screening
Table 2 shows the psychological outcomes at screening. In year 1,
there were no significant differences in anxiety, depression, or total
scores (HADS), or in stress-related behaviour change (HQ)
immediately before MRI and immediately before XRM. The
primary outcome, anticipatory anxiety (SSAI-B) in year 1,
however, was significantly higher before MRI than before XRM
(t¼ 3.00, P¼ 0.003, CI: 0.27–1.30). State anxiety dropped after
screening for both MRI (t¼ 5.83, Po0.0005, CI: 0.92–1.86) and for
XRM (t¼ 3.18, P¼ 0.002, CI: 0.34–1.42), and there was no
significant difference in state anxiety after MRI compared with
after XRM (t¼ 1.075, P¼ 0.28, CI: 0.22 to 0.77). The difference in
state anxiety before MRI and before XRM was not statistically
significant in year 2 (t¼ 1.86, P¼ 0.063, CI: 0.03 to 1.23), but
re-emerged in year 3 (t¼ 2.30, P¼ 0.022, CI: 0.134–1.75). The
difference was not significant for women returning for scans in
year 4 (t¼ 1.17, P¼ 0.242, CI: 0.42 to 1.66).
In year 1, immediately after MRI and XRM, 13.5% of women
reported finding MRI ‘extremely’, ‘very’, or ‘moderately’ distres-
sing, compared with 7.8% of women finding XRM ‘extremely’,
‘very’, or ‘moderately’ distressing. This difference was significant
(Z¼2.83, P¼ 0.005). Magnetic resonance imaging scans are
rated as less distressing in subsequent years, and there is no
statistically significant difference between how distressing women
find MRI and XRM in years 2, 3, and 4. If the key category is taken
as ‘extremely distressing’, then immediately after MRI, 4.4% of
women rated MRI as extremely distressing, compared with 1.1%
of women rating XRM extremely distressing immediately after
XRM (w2¼ 0.554, P¼ 0.55).
There were very high levels of overall satisfaction with
both procedures (MRI-96.3% (68.4% were ‘very satisfied’) and
XRM-97.7% (65.5% were ‘very satisfied’)).
Immediately post-MRI, the least acceptable aspects of the
procedure were reported as ‘finding the MRI table uncomfortable’
(69.7% of participants agreed or strongly agreed with this
statement), ‘the noise during the MRI scan’ (69.7%), ‘the injection’
(68.6%), ‘the screening centre for MRI being in a place that was
difficult to get to’ (66.6%), ‘being worried about going into the
scanner’ (54.6%), and ‘feeling uncomfortable lying still’ (54.6%).
Immediately post-XRM, the least acceptable aspects of the
procedure were ‘worry about being exposed to radiation’
(73.5%), ‘finding the mammogram uncomfortable’ (73.0%), ‘the
screening centre for XRM being in a place that was difficult to get
to’ (69.6%), ‘the way I had to stand’ (63.6%), and ‘pain’ (62.0%).
Follow-up at 6 weeks post mammography
Table 3 shows the psychological outcomes at 6-week follow-up.
At 6 weeks after the year 1 scans, women were significantly less
anxious (HADS; t¼ 3.93, Po0.0005, CI: 1.75 to 1.48) and less
depressed (HADS; t¼ 2.00, P¼ 0.045, CI: 0.84 to 0.01) than they
had been at baseline. Low levels of anxiety and depression were
consistently reported at 6 weeks after the scans in subsequent
years. In terms of clinically significant categories, there was no
Table 1 Description of participants (from 527 background questionnaires)
Sociodemographic characteristics
Age (years; n¼ 525) Median, 40 Range, 31–55
Marital status (n¼ 499) Married/living with
a partner, 79.0%
Single, 7.8% Divorced/separated,
12.4%
Widowed, 0.8%
Ethnic origin (n¼ 525) White, 97.7% Pakistani, 0.2% Indian, 1.3% Chinese, 0.2% Other, 0.6%
Age on leaving full-time education (n¼ 526) 14–16, 39.5% 16–18, 37.6% 18–21, 10.6% 21+, 12.2%
Currently employed (n¼ 524) Yes, 76.3% No, 23.7%
Have children (n¼ 523) Yes, 85.5% No, 14.5%
No of children (n¼ 457) Median, 2 Range, 1–7
Taking medication
Anxiety (n¼ 495) Yes, 4.6% No, 95.4%
Depression (n¼ 505) Yes, 4.8% No, 95.2%
Sleeplessness (n¼ 505) Yes, 3.6% No, 96.4%
Screening experiences
Previously had MRI scan (n¼ 519) Yes, 25.0% No, 75.0%
Found previous MRI scan distressing
(n¼ 128)
Extremely, 3.9% Very, 2.3% Moderately, 6.3% A little, 14.8% Not at all, 72.7%
Previously had XRM (n¼ 522) Yes, 82.6% No, 17.4%
Found previous XRM scan distressing
(n¼ 426)
Extremely, 2.3% Very, 0.2% Moderately, 5.6% A little, 18.3% Not at all, 73.5%
Undertake breast self-examination
(BSE; n¼ 522)
Yes, 87.2% No, 12.8%
Finds BSE distressing (n¼ 448) Extremely, 0.9% Very, 0.4% Moderately, 4.7% A little, 10.9% Not at all, 83.0%
Feels confident about BSE (n¼ 456) Extremely, 3.3% Very, 13.2% Moderately, 51.3% A little, 20.2% Not at all, 12.1%
Has clinical breast examinations
(CBE; n¼ 524)
Yes, 90.6% No, 9.4%
Finds CBE distressing (n¼ 456) Extremely, 0.9% Very, 1.3% Moderately, 3.9% A little, 13.2% No at all, 80.7%
Feels confident about doctors’
CBE ability (n¼ 475)
Extremely, 30.7% Very, 48.2% Moderately, 18.1% A little, 1.7% Not at all, 1.3%
Baseline psychological measures
Hospital Anxiety and Depression Scale
Anxiety (n¼ 526) Mean (s.d.), 6.90 (4.16) Normal range, 61.8% Borderline, 18.6% Clinically significant, 19.6%
Depression (n¼ 526) Mean (s.d.), 3.49 (3.31) Normal range, 86.3% Borderline, 9.7% Clinically significant, 4.0%
Total distress (n¼ 526) Mean (s.d.), 10.4 (6.79)
Health questionnaire (n¼ 527) Mean (s.d.), 7.17 (1.83)
Abbreviations: MRI¼magnetic resonance imaging; XRM¼X-ray mammography.
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Table 2 Psychological outcomes at screening (values are given as mean (s.d.))
Pre MRI Post MRI Pre XRM Post XRM
Year 1
556 Questionnaires
completed
562 Questionnaires
completed
436 Questionnaires
completed
441 Questionnaires
completed
Primary outcome
SSAI-B 12.1 (4.01); n¼ 546, t¼ 3.00, P¼ 0.003,
CI 0.27–1.30
10.7 (3.84); n¼ 542 11.3 (4.09); n¼ 429 10.5 (3.94); n¼ 426
Secondary outcomes
HADS anxiety 6.50 (4.17)
Normal, 62.5%
Borderline, 20.2%
Clinically significant, 17.3%
n¼ 555
6.49 (4.14)
Normal, 62.4%
Borderline, 17.9%
Clinically significant, 19.7%
n¼ 431
HADS depression 2.83 (3.14)
Normal, 89.7%
Borderline, 8.2%
Clinically significant, 2.2%
n¼ 551
2.90 (3.21)
Normal, 89.6%
Borderline, 7.0%
Clinically significant, 3.5%
n¼ 431
HADS total distress 9.32 (6.68); n¼ 551 9.37 (6.66); n¼ 431
HQ 7.11 (1.87); n¼ 552 6.93 (1.69); n¼ 428
Year 2 342 Questionnaires
completed
345 Questionnaires
completed
296 Questionnaires
completed
303 Questionnaires
completed
SSAI-B 11.4 (3.94); n¼ 335 10.3 (3.76); n¼ 329 10.8 (4.08); n¼ 281 10.3 (3.84); n¼ 296
HADS anxiety 5.92 (4.29)
Normal, 67.6%
Borderline, 16.8%
Clinically significant, 15.6%
n¼ 340
5.71 (4.18)
Normal, 71.4%
Borderline, 13.9%
Clinically significant, 14.6%
n¼ 294
HADS depression 2.69 (3.43)
Normal, 89.0%
Borderline, 7.4%
Clinically significant, 3.6%
n¼ 337
2.46 (3.23)
Normal, 89.5%
Borderline, 7.8%
Clinically significant, 2.7%
n¼ 294
HADS total distress 8.61 (6.99); n¼ 337 8.15 (6.71); n¼ 294
HQ 6.98 (1.96); n¼ 336 7.00 (1.87); n¼ 292
Year 3 204 Questionnaires
completed
208 Questionnaires
completed
179 Questionnaires
completed
180 Questionnaires
completed
SSAI-B 11.4 (4.05); n¼ 198, t¼ 2.30,
P¼ 0.022, CI: 0.22–0.77
10.0 (3.84); n¼ 205 10.5 (3.86); n¼ 178 9.99 (3.61); n¼ 178
HADS anxiety 5.62 (4.19)
Normal, 70.6%
Borderline, 15.9%
Clinically significant, 13.4%
n¼ 201
5.49 (4.00)
Normal, 72.7%
Borderline, 14.8%
Clinically significant, 12.5%
n¼ 176
HADS depression 2.58 (3.30)
Normal, 87.5%
Borderline, 9.5%
Clinically significant, 3.0%
n¼ 200
2.58 (3.24)
Normal, 87.6%
Borderline, 10.7%
Clinically significant, 1.7%
n¼ 177
HADS total distress 8.20 (6.82); n¼ 198 8.09 (6.56); n¼ 174
HQ 6.90 (1.74); n¼ 203 6.89 (1.79); n¼ 178
Year 4 122 Questionnaires
completed
122 Questionnaires
completed
97 Questionnaires
completed
110 Questionnaires
completed
SSAI-B 10.8 (3.81); n¼ 119 9.59 (3.18); n¼ 116 10.1 (3.92); n¼ 92 9.72 (3.11); n¼ 109
HADS anxiety 5.20 (4.05)
Normal, 71.4%
Borderline, 15.1%
Clinically significant, 13.4%
n¼ 119
4.98 (3.91)
Normal, 74.2%
Borderline, 15.5%
Clinically significant, 10.3%
n¼ 97
HADS depression 2.53 (3.17)
Normal, 89.3%
Borderline, 8.3%
Clinically significant, 2.5%
n¼ 121
2.40 (3.15)
Normal, 88.4%
Borderline, 8.4%
Clinically significant, 3.2%
n¼ 96
HADS total distress 7.80 (6.66); n¼ 118 7.33 (6.42); n¼ 95
HQ 6.88 (1.73); n¼ 121 6.96 (1.82); n¼ 96
Abbreviations: HADS¼Hospital Anxiety and Depression Scale; HQ¼Health Questionnaire; MRI¼magnetic resonance imaging; SSAI-B¼ Spielberger State Anxiety Inventory;
XRM¼X-ray mammography. Bolded figures denote significant results.
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significant difference in the proportion of women falling into the
HADS normal, borderline, or clinically significant categories of
anxiety at baseline compared with follow-up (w2¼ 8.23, P¼ 0.083,
CI: 0.08–0.09). However, there was a significant difference for
depression; significantly more women moved from the borderline
category of depression into the normal range at follow-up
(w2¼ 15.3, P¼ 0.04, CI: 0.01–0.01).
With regard to the primary outcome (delayed MRI and XRM-
related distress (IoE scale)), significantly more women reported
intrusive MRI-related thoughts than intrusive XRM-related
thoughts (t¼ 2.75, P¼ 0.006, CI: 0.12–0.72). This accounted for
significantly greater total subjective MRI-related distress (IoE)
compared with total subjective XRM-related distress (t¼ 2.47,
P¼ 0.014, CI: 0.15–1.33). This effect was not related to previous
screening experience: those having had an MRI scan had similar
levels of intrusive MRI-related thoughts than those for whom the
procedure was new (t¼ 1.16, P¼ 0.24). The level of avoidant MRI-
related thoughts compared with avoidant XRM-related thoughts
(IoE) showed a non-significant trend (t¼ 1.88, P¼ 0.060, CI: 0.01
to 0.62).
In year 2, women reported significantly more intrusive MRI-
related thoughts compared with intrusive XRM-related thoughts
(t¼ 2.73, P¼ 0.007, CI: 0.14–0.84), significantly more avoidant
MRI-related thoughts compared with XRM-related thoughts
(t¼ 2.92, P¼ 0.004, CI: 0.19–1.00), and more total subjective
MRI-related distress compared with total subjective XRM-related
distress (t¼ 2.96, P¼ 0.003, CI: 0.37–1.82). Differences did not
reach statistical significance in years 3 and 4.
Six weeks after the year 1 scans, 88% of participants stated that
they intended to return for MRI compared with 96.3% for XRM
(Z¼4.58, Po0.0005). This significant difference in intention to
re-attend was maintained in years 2 (Z¼3.96, Po0.0005) and
3 (Z¼2.25, P¼ 0.024). Intention to return for MRI is strongly
related to intrusive thoughts about MRI at follow-up (as assessed
using the IoE scale). The mean score for intrusive thoughts about
MRI of those intending the return was 8.90 (s.d. 3.32) compared
with 13.2 (s.d. 5.32) of those unwilling or unsure about coming
back (t¼ 7.98, Po0.0005, CI: 3.30–5.45). However, it is well
known that behavioural intentions do not always translate into
behaviour. Unsurprisingly, women who indicated that they did not
intend to return for MRI, or who were unsure about whether to
re-attend, were significantly more likely not to return for screening
(w2¼ 8.81, P¼ 0.012). However, 4 of the 12 women who indicated
that they did not intend to return, and 10 of the 38 women who
said they were unsure about returning in year 1, did in fact return
for screening in year 2.
Table 3 Psychological outcomes at 6-week follow-up
Year 1 Year 2 Year 3 Year 4
481 Questionnaires
completed
287 Questionnaires
completed
169 Questionnaires
completed
108 Questionnaires
completed
Primary outcomes
IoE total subjective distress MRI 19.3 (7.01); n¼ 443, t¼ 2.47,
P¼ 0.014, CI: 0.15–1.33a
18.8 (6.94); n¼ 270, t¼ 2.96,
P¼ 0.003, CI: 0.37–1.82a
17.8 (5.37); n¼ 165 17.8 (5.82); n¼ 104
IoE intrusive thoughts MRI 9.15 (3.55); n¼ 446, t¼ 2.75,
P¼ 0.006, CI: 0.12–0.72a
8.73 (3.32); n¼ 272, t¼ 2.73,
P¼ 0.007, CI: 0.14–0.84a
8.28 (2.60); n¼ 167 8.31 (2.73); n¼ 108
IoE avoidant thoughts MRI 10.2 (3.84); n¼ 444 10.1 (3.93); n¼ 271, t¼ 2.92,
P¼ 0.004, CI 0.19–1.00)a
9.55 (3.08); n¼ 165 9.54 (3.43); n¼ 104
IoE total subjective distress XRM 18.6 (5.24); n¼ 416 17.8 (5.25); n¼ 255 17.4 (4.46); n¼ 154 17.2 (4.43); n¼ 96
IoE intrusive thoughts XRM 8.72 (2.66); n¼ 425 8.26 (2.48); n¼ 258 7.94 (2.03); n¼ 156 7.83 (1.87); n¼ 98
IoE avoidant thoughts XRM 9.88 (2.93); n¼ 419 9.59 (3.09); n¼ 257 9.47 (2.84); n¼ 154 9.43 (2.99); n¼ 96
Secondary outcomes
HADS anxiety 5.87 (4.09)
Normal, 67.7%
Borderline, 19.0%
Clinically significant, 13.3%
n¼ 474, t¼ 3.93, Po0.0005,
CI: 1.75 to 1.48a
(compared with baseline)
5.50 (3.99)
Normal, 70.4%
Borderline, 17.0%
Clinically significant, 12.6%
n¼ 277
5.35 (3.85)
Normal, 71.2%
Borderline, 19.0%
Clinically significant, 9.8%
n¼ 163
5.11 (4.22)
Normal, 73.8%
Borderline, 14.0%
Clinically significant,
12.1%
n¼ 107
HADS depression 3.07 (3.38)
Normal, 87.1%
Borderline, 8.9%
Clinically significant, 4.0%
n¼ 473, t¼ 2.00, Po0.045,
CI: 0.84 to 0.01a
(compared with baseline)
2.92 (3.49)
Normal, 88.1%
Borderline, 8.8%
Clinically significant, 3.1%
n¼ 261
2.61 (3.12)
Normal, 87.3%
Borderline, 10.2%
Clinically significant, 2.4%
n¼ 166
2.80 (3.71)
Normal, 88.8%
Borderline, 7.5%
Clinically significant,
3.7%
n¼ 107
HADS total distress 8.93 (6.87); n¼ 470, t¼ 3.30,
P¼ 0.001 CI: 0.59–2.33a
(compared with baseline)
8.69 (6.82) n¼ 256 7.96 (6.39); n¼ 166 7.83 (7.19); n¼ 107
HQ 6.96 (2.07); n¼ 477 6.86 (2.29); n¼ 264 6.80 (1.72); n¼ 166 6.74 (2.00); n¼ 108
Intention to return for MRI Yes, 88.0%
No, 2.6%
Unsure, 8.4%
n¼ 454, Z¼4.58, Po0.0005b
Yes, 89.1%
No, 5.8%
Unsure, 5.1%
n¼ 274, Z¼3.96, Po0.0005b
Yes, 94.6%
No, 2.4%
Unsure, 3.0%
n¼ 166, Z¼2.25, P¼ 0.024b
Yes, 89.6%
No, 6.6%
Unsure, 3.8%
n¼ 106
Intention to return for XRM Yes, 96.3%
No, 2.1%
Unsure, 1.6%
n¼ 434
Yes, 95.5%
No, 1.9%
Unsure, 2.6%
n¼ 267
Yes, 98.1%
No, 0.6%
Unsure, 1.3%
n¼ 156
Yes, 92.7%
No, 5.2%
Unsure, 3.1%
n¼ 96
Abbreviations: HADS¼Hospital Anxiety and Depression Scale; HQ¼Health Questionnaire; IoE¼ Impact of Events Scale; MRI¼magnetic resonance imaging; XRM¼X-ray
mammography. Values given in bold denote significant results. at-Test used to compare means. bMann–Whitney U-test used to compare percentages.
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Over the course of the study, 27 women declined MRI outright,
and 16 women attended MRI, but experienced a ‘technical failure’
(for example, they were too big for the scanner or staff were unable
to get venous access for the contrast agent). A total of 106 women
withdrew over the course of the study. The most common reasons
for withdrawal were receiving a negative gene test; receiving a
breast cancer diagnosis; stress/personal reasons; claustrophobia/
scan uncomfortable; having undergone prophylactic mastectomy;
and not being able to contact participants in subsequent years.
We had been concerned that the order of the scans, that is,
whether women received XRM or MRI first, might affect the
results. Specifically, the concern was that women would be more
anxious for their first scan, irrespective of whether it was XRM or
MRI that was carried out first. Unfortunately, it was not practical
to randomise individual women to receiving MRI or XRM first.
However, some centres undertook to perform MRI first and others
XRM first, so that a sub-analyses of order effects could be
undertaken. Order effects were not significant. Differences in
anxiety and acceptability between screening centres were greater
than any effects of receiving MRI or XRM first. The centre with the
lowest mean anticipatory anxiety before MRI (as assessed using
the SSAI-B) scored 10.7 (s.d. 3.4), compared with the centre with
the highest mean pre-MRI anticipatory anxiety score of 16.7
(s.d. 4.8). The difference between these two centres was highly
significant (t¼ 4.0, Po0.0005, CI: 2.98–9.02). The differences in
anticipatory anxiety are unrelated to the size of the screening
centre. Environmental and interpersonal factors such as the ethos
of the centre and communication skills of staff are likely to be
more important.
DISCUSSION
Throughout the study, low levels of psychological morbidity, as
assessed by the HADS, were observed. Even at baseline, in which
the mean scores for anxiety and depression were highest, only
19.6% of women met the criteria for clinically significant anxiety
and 4% met the criteria for clinically significant depression. These
figures are broadly representative of HADS scores seen for women
in the general UK population (Crawford et al, 2001). The
significant difference noted in mean scores of HADS depression
represents small changes in mean scores with a relatively large
sample size. It does not represent more clinically meaningful
changes in the numbers of women falling into normal, borderline,
or clinically significant categories of distress.
Hospital Anxiety and Depression Scale distress was highest at
baseline (1-month before the scans) and lowest at follow-up
(6 weeks after the scans). In this study, when they completed the
baseline questionnaires, women knew they would be attending for
screening in the near future. In the context of the National Breast
Screening Programme, we used the HADS to assess mental state
before the women were invited to attend screening and found that
there was a significant decline when they attended for screening
(Walker et al, 1994). It may be that in a screening context, HADS
scores tend to reduce between the first and second administration.
However, the observed findings in this study are consistent with
the hypothesis that women may be most psychologically vulner-
able at the point of recruitment into the study, and in the lead up
to the scans; this has obvious implications for the timing of
appropriate information and support. The HADS data are also
consistent with the view that the long-term impact of screening on
mental health is positive.
Women found MRI to be significantly more distressing than
conventional XRM (ad hoc rating scale). They were more anxious
(STAI-B) before MRI than before XRM. Anxiety dropped
significantly during both procedures, and there was no significant
difference in state anxiety afterwards. It might have been expected
that anticipatory anxiety would habituate with repeated exposure.
However, although the difference in anticipatory anxiety was not
significant in year 2, it re-emerged in year 3.
In all, 13.5% of women reported that they had found MRI
‘extremely’, ‘very’, or ‘moderately’ distressing compared with only
7.8% of women finding XRM ‘extremely’, ‘very’, or ‘moderately’
distressing. The first MRI scan was the most distressing: the
number of women reporting distress fell in subsequent years. It
should be noted, however, that both procedures were highly
acceptable and that the vast majority of women reporting little or
no MRI- or XRM-related distress in year 1 (86.5 and 92.2%,
respectively). Moreover, there were very high levels of satisfaction
with both procedures (96.3 and 97.7%, respectively).
With regard to the long-term effects of screening, HADS distress
was consistently lowest at follow-up (6 weeks after the scans),
which suggests that the overall psychological impact of screening
was positive. However, with regard to MRI- and XRM-specific
distress measured by the IOE scale at follow-up, women reported
significantly more intrusive thoughts about MRI and more total
MRI-related subjective distress compared with XRM. This persist-
ing MRI-specific distress was not restricted to year 1: 6 weeks
after the year 2 scans, women also reported significantly more
MRI- than XRM-specific distress.
Six weeks after the scans, the vast majority of women indicated
that they planned to return for scans the following year. However,
significantly more women expressed reluctance to re-attend for MRI
than XRM. This effect was not restricted to the first year, but was
present in year 2. In the total cohort, 106 of 838 (12.6%) women
were excluded or withdrew before year 1 scans because of logistical
problems. The most commonly cited reasons for withdrawing from
the study were receiving a negative gene test; receiving a breast
cancer diagnosis; stress/personal reasons; claustrophobia/scan
uncomfortable; having undergone prophylactic mastectomy; not
being able to contact participants in subsequent years.
We believe these results can be generalised to the wider
population of women at genetic risk for breast cancer. In the
wider MARIBS study, 732 women were screened in year 1 (Warren
et al, 2005). The psychological arm of the study included 616 of
these, and the majority of those 116 who were not included were
women who were recruited in the first year of MARIBS, before the
psychological study had commenced. On the whole, response rates
were good (71–91% in year 1). The bulk of missing data, including
most of the women lost to follow-up, came from 1 of the 22
screening centres, where completing questionnaires was difficult
due to practical constraints and the screening environment; hence,
the data may be even more representative than the trial profile
(Figure 1) would suggest.
The categories of women eligible for screening under the UK
NICE guidelines (McIntosh et al, 2006) reflect closely the inclusion
criteria for the MARIBS study. The results are also relevant to
higher risk groups in terms of the American Cancer Society
guidelines (Saslow et al, 2007), although we are unable to comment
on possible cross-cultural psychosocial differences.
We had intended to look at the impact of ‘false-positive’ MRI
scans, that is, to look at the levels of anxiety generated by being
recalled for a second MRI scan, which ultimately turned out to be
normal. A second MRI scan was undertaken when an anomalous
result was seen on MRI, but not on XRM. There were fewer false-
positive MRI scans that had been anticipated because of the better
specificity of MRI than had been predicted at the outset of the
study. A total of 10.7% of women were recalled for further
assessment following MRI (Leach et al, 2005), resulting in a total of
85 recalls, 25 of which were positive, in year 1. Psychological data
were collected for 27 women recalled for second scans in year
1 and for 11 women who were recalled in year 2. The data did not
indicate a significant increase in anxiety before the second scan,
although the sample sizes are too small to make any general
conclusions about the impact of false-positive MRI scans.
However, MRI and/or cancer-related distress were not commonly
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cited reasons for withdrawing from MARIBS. The reasons for
withdrawing were diverse. Overall, in the course of the study, the
five most common reasons for withdrawal were negative predictive
gene test (n¼ 30), the development of breast cancer (n¼ 35),
personal reasons or stress (n¼ 19), claustrophobia (n¼ 12), and
prophylactic mastectomy (n¼ 28).
For logistical and ethical reasons, women who went on for
further investigations, such as biopsy, were excluded from the
psychology study.
In conclusion, from a psychological point of view, it appears that
both MRI and XRM are acceptable techniques for screening the
majority of women with a family history of breast cancer, at least
within the context of a multicentre randomised controlled trial.
Although small changes in mean HADS anxiety scores were noted,
there were no clinically meaningful changes in either anxiety or
depression throughout the course of screening, as evidenced by
changes in the proportion of women falling into normal, borderline,
or clinically significant categories. The overwhelming majority of
women reported little or no distress and feelings of being satisfied
with both procedures. However, in terms of our primary outcomes,
we did find that MRI was more distressing than XRM, and women
experienced significantly more anticipatory anxiety before MRI and
significantly more MRI-related distress 6 weeks later. Most women
stated that they intended to re-attend for screening, although
significantly more women expressed a reluctance to re-attend for
MRI compared with XRM. These effects are most marked for the
first MRI, but remain in subsequent years.
Given the proven benefits of MRI screening in this population of
high-risk women, these data point to an urgent need to develop
and evaluate strategies of providing information and support to
women undergoing MRI. These strategies should have the aim of
minimising distress and optimising re-attendance, and be realistic
within the context of a national screening programme.
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